Literature DB >> 28961947

Ebola Virus Inactivation by Detergents Is Annulled in Serum.

Jeroen J A van Kampen1, Andrei Tintu2, Henk Russcher2, Pieter L A Fraaij1,3, Chantal B E M Reusken1, Mikel Rijken1, Jaap J van Hellemond4, Perry J J van Genderen5, Rob Koelewijn4, Menno D de Jong6, Elaine Haddock7, Robert J Fischer7, Vincent J Munster7, Marion P G Koopmans1.   

Abstract

Background: Treatment of blood samples from hemorrhagic fever virus (HFV)-infected patients with 0.1% detergents has been recommended for virus inactivation and subsequent safe laboratory testing. However, data on virus inactivation by this procedure are lacking. Here we show the effect of this procedure on diagnostic test results and infectious Ebola virus (EBOV) titers.
Methods: Serum and whole-blood samples were treated with 0.1% or 1% sodium dodecyl sulfate (SDS) or 0.1% Triton X-100 and assayed for clinical chemistry and malaria antigen detection. Infectious EBOV titers were determined in SDS-treated plasma and whole blood from EBOV-infected nonhuman primates (NHPs). Infectious titers of EBOV or herpes simplex virus type 1 (HSV-1) in detergents-treated cell culture medium containing various serum concentrations were determined.
Results: Laboratory test results were not affected by 0.1% detergent treatment of blood samples, in contrast with 1% SDS treatment. However, 0.1% detergent treatment did not inactivate EBOV in blood samples from infected NHPs. Experiments with cell culture medium showed that virus inactivation by detergents is annulled at physiological serum concentrations. Conclusions: Treatment of blood samples with 0.1% SDS or Triton X-100 does not inactivate EBOV. Inactivation protocols for HFV should be validated with serum and whole blood.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Ebola; Triton; detergent; inactivation; sodium dodecyl sulfate (SDS)

Mesh:

Substances:

Year:  2017        PMID: 28961947      PMCID: PMC5853228          DOI: 10.1093/infdis/jix401

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Influence of practicable virus inactivation procedures on tests for frequently measured analytes in plasma.

Authors:  Martin Hersberger; Charly Nusbaumer; André Scholer; Verena Knöpfli; Arnold von Eckardstein
Journal:  Clin Chem       Date:  2004-05       Impact factor: 8.327

2.  Evaluation of two automated instruments for pre-transfusion testing: AutoVue Innova and Techno TwinStation.

Authors:  So Youn Shin; Kye Chul Kwon; Sun Hoe Koo; Jong Woo Park; Chi Seon Ko; Jeong Hoon Song; Ji Youn Sung
Journal:  Korean J Lab Med       Date:  2008-06

3.  Update: management of patients with suspected viral hemorrhagic fever--United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-06-30       Impact factor: 17.586

4.  Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation.

Authors:  L H Elliott; J B McCormick; K M Johnson
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

5.  Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.

Authors:  F C Krebs; S R Miller; D Malamud; M K Howett; B Wigdahl
Journal:  Antiviral Res       Date:  1999-10       Impact factor: 5.970

6.  Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients.

Authors:  Massimo Tempestilli; Luigia Pucci; Stefania Notari; Antonino Di Caro; Concetta Castilletti; Maria Rosaria Rivelli; Chiara Agrati; Leopoldo Paolo Pucillo
Journal:  Clin Chem Lab Med       Date:  2015-11       Impact factor: 3.694

7.  Preclinical evaluation of docusate as protective agent from herpes simplex viruses.

Authors:  Y Gong; A Wen; D Cheung; M Wong; S L Sacks
Journal:  Antiviral Res       Date:  2001-10       Impact factor: 5.970

8.  Thermal stability and inactivation of hepatitis C virus grown in cell culture.

Authors:  Hongshuo Song; Jin Li; Shuang Shi; Ling Yan; Hui Zhuang; Kui Li
Journal:  Virol J       Date:  2010-02-18       Impact factor: 4.099

9.  Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.

Authors:  Andrea Marzi; Patrick W Hanley; Elaine Haddock; Cynthia Martellaro; Gary Kobinger; Heinz Feldmann
Journal:  J Infect Dis       Date:  2016-08-05       Impact factor: 5.226

10.  Effects of viral hemorrhagic fever inactivation methods on the performance of rapid diagnostic tests for Plasmodium falciparum.

Authors:  M R Loutfy; M Assmar; D C Hay Burgess; K C Kain
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  9 in total

1.  Compatibility of Maximum-Containment Virus-Inactivation Protocols With Identification of Bacterial Coinfections by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.

Authors:  M Jeremiah Matson; Frida Stock; W Lesley Shupert; Trenton Bushmaker; Friederike Feldmann; Wendy B Bishop; Karen M Frank; John P Dekker; Daniel S Chertow; Vincent J Munster
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

2.  Inactivation Methods for Experimental Nipah Virus Infection.

Authors:  Lina Widerspick; Cecilia Alejandra Vázquez; Linda Niemetz; Michelle Heung; Catherine Olal; András Bencsik; Christoph Henkel; Anneke Pfister; Jesús Emanuel Brunetti; Indre Kucinskaite-Kodze; Philip Lawrence; César Muñoz Fontela; Sandra Diederich; Beatriz Escudero-Pérez
Journal:  Viruses       Date:  2022-05-15       Impact factor: 5.818

3.  Effectiveness of Dettol Antiseptic Liquid for Inactivation of Ebola Virus in Suspension.

Authors:  Todd A Cutts; M Khalid Ijaz; Raymond W Nims; Joseph R Rubino; Steven S Theriault
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

Review 4.  Laboratory management of Crimean-Congo haemorrhagic fever virus infections: perspectives from two European networks.

Authors:  Barbara Bartolini; Cesare Em Gruber; Marion Koopmans; Tatjana Avšič; Sylvia Bino; Iva Christova; Roland Grunow; Roger Hewson; Gulay Korukluoglu; Cinthia Menel Lemos; Ali Mirazimi; Anna Papa; Maria Paz Sanchez-Seco; Aisha V Sauer; Hervè Zeller; Carla Nisii; Maria Rosaria Capobianchi; Giuseppe Ippolito; Chantal B Reusken; Antonino Di Caro
Journal:  Euro Surveill       Date:  2019-01

5.  Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections.

Authors:  M M Remy; M Alfter; M-N Chiem; M T Barbani; O B Engler; F Suter-Riniker
Journal:  Clin Microbiol Infect       Date:  2018-10-28       Impact factor: 8.067

Review 6.  New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): Focus on environmental survival and germicide susceptibility.

Authors:  David J Weber; Emily E Sickbert-Bennett; Hajime Kanamori; William A Rutala
Journal:  Am J Infect Control       Date:  2019-06       Impact factor: 2.918

7.  Validation of Inactivation Methods for Arenaviruses.

Authors:  Silke Olschewski; Anke Thielebein; Chris Hoffmann; Olivia Blake; Jonas Müller; Sabrina Bockholt; Elisa Pallasch; Julia Hinzmann; Stephanie Wurr; Neele Neddersen; Toni Rieger; Stephan Günther; Lisa Oestereich
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

8.  Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives.

Authors:  Stephen R Welch; Katherine A Davies; Hubert Buczkowski; Nipunadi Hettiarachchi; Nicole Green; Ulrike Arnold; Matthew Jones; Matthew J Hannah; Reah Evans; Christopher Burton; Jane E Burton; Malcolm Guiver; Patricia A Cane; Neil Woodford; Christine B Bruce; Allen D G Roberts; Marian J Killip
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

9.  Evaluation of the SARS-CoV-2 Inactivation Efficacy Associated With Buffers From Three Kits Used on High-Throughput RNA Extraction Platforms.

Authors:  Ruth E Thom; Lin S Eastaugh; Lyn M O'Brien; David O Ulaeto; James S Findlay; Sophie J Smither; Amanda L Phelps; Helen L Stapleton; Karleigh A Hamblin; Simon A Weller
Journal:  Front Cell Infect Microbiol       Date:  2021-09-16       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.